- Title
- GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
- Creators
- Shibani Nicum - University College LondonChristian Marth - AGO-A and Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaDearbhaile C. Collins - Cork University HospitalJan Kümmel - University Hospital OstravaFlora Zagouri - Alexandra HospitalYakir Segev - Carmel Medical CenterMaria Cristina Petrella - MITO and Oncologia Medica Ginecologica, Azienda Universitaria Ospedaliera Careggi, Firenze, ItalyHeini J. Lassus - Helsinki University HospitalKeiichi Fujiwara - Saitama Medical UniversityJian Liu Wang - Peking University People's HospitalChien-Hsing Lu - Taichung Veterans General HospitalAtthapon Jaishuen - Mahidol UniversityM. Valeria Cáceres - Department of Medical Oncology, Instituto de Oncología Ángel H. Roffo, Buenos Aires, ArgentinaRuffo Freitas-Junior - Universidade Federal de GoiásSarah Crafton - Allegheny Health NetworkDestin Black - Willis-Knighton Cancer CenterBrian M. Slomovitz - Mount Sinai Medical CenterRobert Orlowski - Merck & Co., Inc., Rahway, United States of AmericaStephan Kruger - Merck & Co., Inc., Rahway, United States of AmericaLili Yao - Merck & Co., Inc., Rahway, United States of AmericaBradley Monk - Gynecologic Oncology Group
- Publication Details
- International journal of gynecological cancer, Vol.35(11), p.102611
- Publisher
- Elsevier Inc
- Identifiers
- 991006235737802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
International journal of gynecological cancer, Vol.35(11), p.102611
11/2025
Metrics
3 Record Views